CY1120419T1 - Ενισχυση της μεταφορας θεραπευτικων μοριων μεσω του αιματοεγκεφαλικου φραγμου - Google Patents
Ενισχυση της μεταφορας θεραπευτικων μοριων μεσω του αιματοεγκεφαλικου φραγμουInfo
- Publication number
- CY1120419T1 CY1120419T1 CY20181100721T CY181100721T CY1120419T1 CY 1120419 T1 CY1120419 T1 CY 1120419T1 CY 20181100721 T CY20181100721 T CY 20181100721T CY 181100721 T CY181100721 T CY 181100721T CY 1120419 T1 CY1120419 T1 CY 1120419T1
- Authority
- CY
- Cyprus
- Prior art keywords
- blood
- strengthening
- transfer
- transport
- therapeutic molecules
- Prior art date
Links
- 230000004888 barrier function Effects 0.000 title 1
- 238000005728 strengthening Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 4
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261585039P | 2012-01-10 | 2012-01-10 | |
| PCT/US2013/021041 WO2013106577A2 (en) | 2012-01-10 | 2013-01-10 | Enhancement of transport of therapeutic molecules across the blood brain barrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120419T1 true CY1120419T1 (el) | 2019-07-10 |
Family
ID=47633561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100721T CY1120419T1 (el) | 2012-01-10 | 2018-07-11 | Ενισχυση της μεταφορας θεραπευτικων μοριων μεσω του αιματοεγκεφαλικου φραγμου |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9676849B2 (enExample) |
| EP (1) | EP2802606B1 (enExample) |
| JP (1) | JP6247226B2 (enExample) |
| KR (1) | KR102104686B1 (enExample) |
| CN (1) | CN104159922B (enExample) |
| AU (1) | AU2013207927B2 (enExample) |
| BR (1) | BR112014016887A2 (enExample) |
| CA (1) | CA2860579A1 (enExample) |
| CY (1) | CY1120419T1 (enExample) |
| DK (1) | DK2802606T3 (enExample) |
| EA (1) | EA201491346A1 (enExample) |
| ES (1) | ES2677111T3 (enExample) |
| HR (1) | HRP20180937T1 (enExample) |
| HU (1) | HUE039033T2 (enExample) |
| IL (1) | IL233246B (enExample) |
| LT (1) | LT2802606T (enExample) |
| MX (1) | MX350378B (enExample) |
| NZ (1) | NZ626620A (enExample) |
| PL (1) | PL2802606T3 (enExample) |
| PT (1) | PT2802606T (enExample) |
| SI (1) | SI2802606T1 (enExample) |
| TR (1) | TR201809743T4 (enExample) |
| WO (1) | WO2013106577A2 (enExample) |
| ZA (1) | ZA201404873B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6148729B2 (ja) | 2012-07-04 | 2017-06-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 共有結合している抗原−抗体結合体 |
| BR112016014945A2 (pt) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugado, formulação farmacêutica e uso |
| KR20160104628A (ko) | 2014-01-03 | 2016-09-05 | 에프. 호프만-라 로슈 아게 | 이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도 |
| EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| MX375841B (es) * | 2014-03-06 | 2025-03-07 | Nat Res Council Canada | Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos. |
| KR102355310B1 (ko) * | 2014-03-06 | 2022-01-24 | 내셔날 리서치 카운실 오브 캐나다 | 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도 |
| JP6541235B2 (ja) * | 2014-03-06 | 2019-07-10 | ナショナル リサーチ カウンシル オブ カナダ | インスリン様成長因子１受容体特異的抗体及びそれらの使用 |
| JP6391318B2 (ja) * | 2014-06-27 | 2018-09-19 | 学校法人順天堂 | アルツハイマー病予防治療薬のスクリーニング法 |
| WO2016097315A2 (en) * | 2014-12-19 | 2016-06-23 | Medimmune Limited | Blood brain barrier transport molecules and uses thereof |
| AU2016210835B2 (en) | 2015-01-29 | 2021-01-21 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| JP7059494B2 (ja) * | 2016-07-06 | 2022-04-26 | ナショナル リサーチ カウンシル オブ カナダ | 血液脳関門を通過するヒト化抗体及びその使用 |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| EP3551666A4 (en) | 2016-12-12 | 2020-07-29 | National Research Council of Canada | VARIANTS OF ANTIBODIES CROSSING THE HEMATOENCEPHALIC BARRIER AND THEIR USES |
| CA3052058A1 (en) | 2017-01-30 | 2018-08-02 | National Research Council Of Canada | Blood-brain barrier transmigrating compounds and uses thereof |
| US11453701B2 (en) | 2017-08-18 | 2022-09-27 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| JP7369127B2 (ja) * | 2017-12-28 | 2023-10-25 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体 |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| AU2019218786B2 (en) | 2018-02-07 | 2024-05-02 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| WO2019246003A1 (en) * | 2018-06-18 | 2019-12-26 | Anwita Biosciences, Inc. | Anti-mesothelin constructs and uses thereof |
| EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
| US20210161993A1 (en) * | 2018-09-12 | 2021-06-03 | Pvp Labs Pte. Ltd. | Method for accelerated healing of burn wounds |
| CA3115071A1 (en) | 2018-10-04 | 2020-04-09 | University Of Rochester | Improvement of glymphatic delivery by manipulating plasma osmolarity |
| AU2019371814A1 (en) * | 2018-10-29 | 2021-06-17 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CN113284553B (zh) * | 2021-05-28 | 2023-01-10 | 南昌大学 | 一种用于治疗药物成瘾的药物靶点结合能力测试方法 |
| AU2021476277A1 (en) | 2021-12-02 | 2024-06-06 | Linno Pharmaceuticals Inc. | Transferrin binding antibodies and use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1166947A (en) | 1914-10-05 | 1916-01-04 | Paramount Hosiery Form Drying Company | Hosiery-finishing apparatus. |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4849407A (en) | 1986-08-13 | 1989-07-18 | Zymogenetics, Inc. | Biologically active mosaic proteins |
| US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
| US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
| IL78444A (en) | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
| ATE143052T1 (de) | 1986-07-07 | 1996-10-15 | Centocor Inc | Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen |
| NO873164L (no) | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
| IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| CA1339445C (en) | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990014425A1 (en) | 1989-05-22 | 1990-11-29 | Zymogenetics, Inc. | PDGF α-RECEPTOR |
| US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| CA2040099A1 (en) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine kinase negative trkb |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| JPH04334377A (ja) | 1990-12-31 | 1992-11-20 | Akzo Nv | 酸−不安定性リンカー分子 |
| EP0580751A1 (en) | 1991-04-19 | 1994-02-02 | Schering Corporation | Subunit of the human interleukin-3 receptor |
| US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
| US5348856A (en) | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| US6451764B1 (en) | 1995-09-08 | 2002-09-17 | Genentech, Inc. | VEGF-related protein |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| AU729029B2 (en) | 1996-07-03 | 2001-01-25 | Genentech Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
| US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| EP0941120A4 (en) | 1996-11-05 | 2004-08-18 | Bristol Myers Squibb Co | BRANCHED PEPTIDLINKERS |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU762047B2 (en) | 1999-01-06 | 2003-06-19 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
| JP3971108B2 (ja) | 1999-01-06 | 2007-09-05 | ジェネンテック・インコーポレーテッド | インシュリン様成長因子（ｉｇｆ）ｉ突然変異体 |
| SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
| US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
| US7943129B2 (en) * | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| DE60236861D1 (de) | 2001-04-26 | 2010-08-12 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2006083275A2 (en) | 2004-05-21 | 2006-08-10 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
| AU2005307789A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| WO2007036021A1 (en) | 2005-09-27 | 2007-04-05 | National Research Council Of Canada | Blood-brain barrier epitopes and uses thereof |
| EP1986684A2 (en) * | 2006-02-15 | 2008-11-05 | ImClone Systems Incorporated | Functional antibodies |
| NZ581395A (en) | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| JP5826194B2 (ja) * | 2010-03-03 | 2015-12-02 | アブリンクス ナームローゼ フェンノートシャップ | 二パラトープ性ａ−ベータ結合ポリペプチド |
| US8986689B2 (en) * | 2010-04-14 | 2015-03-24 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
-
2013
- 2013-01-10 JP JP2014552303A patent/JP6247226B2/ja not_active Expired - Fee Related
- 2013-01-10 BR BR112014016887A patent/BR112014016887A2/pt not_active Application Discontinuation
- 2013-01-10 CN CN201380004989.7A patent/CN104159922B/zh not_active Expired - Fee Related
- 2013-01-10 NZ NZ626620A patent/NZ626620A/en not_active IP Right Cessation
- 2013-01-10 DK DK13702529.2T patent/DK2802606T3/en active
- 2013-01-10 ES ES13702529.2T patent/ES2677111T3/es active Active
- 2013-01-10 KR KR1020147018724A patent/KR102104686B1/ko not_active Expired - Fee Related
- 2013-01-10 WO PCT/US2013/021041 patent/WO2013106577A2/en not_active Ceased
- 2013-01-10 SI SI201331060T patent/SI2802606T1/en unknown
- 2013-01-10 US US14/370,828 patent/US9676849B2/en active Active
- 2013-01-10 PL PL13702529T patent/PL2802606T3/pl unknown
- 2013-01-10 HR HRP20180937TT patent/HRP20180937T1/hr unknown
- 2013-01-10 AU AU2013207927A patent/AU2013207927B2/en not_active Ceased
- 2013-01-10 PT PT137025292T patent/PT2802606T/pt unknown
- 2013-01-10 EA EA201491346A patent/EA201491346A1/ru unknown
- 2013-01-10 CA CA2860579A patent/CA2860579A1/en active Pending
- 2013-01-10 LT LTEP13702529.2T patent/LT2802606T/lt unknown
- 2013-01-10 EP EP13702529.2A patent/EP2802606B1/en active Active
- 2013-01-10 TR TR2018/09743T patent/TR201809743T4/tr unknown
- 2013-01-10 HU HUE13702529A patent/HUE039033T2/hu unknown
- 2013-01-10 MX MX2014008365A patent/MX350378B/es active IP Right Grant
-
2014
- 2014-06-19 IL IL233246A patent/IL233246B/en active IP Right Grant
- 2014-07-01 ZA ZA2014/04873A patent/ZA201404873B/en unknown
-
2018
- 2018-07-11 CY CY20181100721T patent/CY1120419T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102104686B1 (ko) | 2020-04-24 |
| BR112014016887A2 (pt) | 2018-08-14 |
| AU2013207927B2 (en) | 2017-11-02 |
| SI2802606T1 (en) | 2018-08-31 |
| JP2015509097A (ja) | 2015-03-26 |
| EP2802606A2 (en) | 2014-11-19 |
| US9676849B2 (en) | 2017-06-13 |
| US20150210762A1 (en) | 2015-07-30 |
| ZA201404873B (en) | 2018-12-19 |
| HUE039033T2 (hu) | 2018-12-28 |
| PT2802606T (pt) | 2018-07-13 |
| KR20140112497A (ko) | 2014-09-23 |
| HK1203977A1 (en) | 2015-11-06 |
| MX350378B (es) | 2017-09-05 |
| PL2802606T3 (pl) | 2018-09-28 |
| TR201809743T4 (tr) | 2018-07-23 |
| MX2014008365A (es) | 2014-10-06 |
| WO2013106577A3 (en) | 2013-11-21 |
| CN104159922B (zh) | 2018-03-02 |
| WO2013106577A2 (en) | 2013-07-18 |
| EA201491346A1 (ru) | 2014-11-28 |
| CN104159922A (zh) | 2014-11-19 |
| HRP20180937T1 (hr) | 2018-08-10 |
| AU2013207927A1 (en) | 2014-07-17 |
| EP2802606B1 (en) | 2018-04-25 |
| IL233246B (en) | 2018-07-31 |
| CA2860579A1 (en) | 2013-07-18 |
| IL233246A0 (en) | 2014-08-31 |
| LT2802606T (lt) | 2018-10-10 |
| ES2677111T3 (es) | 2018-07-30 |
| DK2802606T3 (en) | 2018-06-25 |
| NZ626620A (en) | 2016-07-29 |
| JP6247226B2 (ja) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120419T1 (el) | Ενισχυση της μεταφορας θεραπευτικων μοριων μεσω του αιματοεγκεφαλικου φραγμου | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1122073T1 (el) | Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40 | |
| CY1124033T1 (el) | Δοσολογια και χορηγηση μη φουκοζυλιωμενων αντισωματων anti-cd40 | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1124299T1 (el) | Συνδυαστικες θεραπειες που περιλαμβανουν μορια αντισωματων κατα toy lag-3 | |
| CY1125440T1 (el) | Αντι-τιμ-3 αντισωματα και συνθεσεις | |
| CY1123693T1 (el) | Παραγοντες rnai, συνθεσεις και μεθοδοι χρησης αυτων για τη θεραπευτικη αγωγη σχετιζομενων με τρανσθυρετινη (ttr) ασθενειων | |
| CY1121431T1 (el) | Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40 | |
| CY1123256T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
| CY1123515T1 (el) | Μεθοδοι αγωγης μιας ταυπαθειας | |
| CY1121220T1 (el) | Θεραπευτικες συνθεσεις νουκλεασης και μεθοδοι | |
| CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
| CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
| CY1121542T1 (el) | Μορια αντισωματων σε pd-1 και χρηση αυτων | |
| CY1117654T1 (el) | Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης | |
| CY1121379T1 (el) | Πολυθεραπεια για την ισχαιμια | |
| UA117364C2 (uk) | Похідні аматоксину | |
| MX395257B (es) | Anticuerpos para cd40. | |
| BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
| CY1123672T1 (el) | Μεθοδοι αγωγης μιας ταυπαθειας | |
| EA201490029A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201690881A1 (ru) | Соединения-ингибиторы аутотаксина | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| EA201592107A1 (ru) | Доставка иммунодепрессантов, имеющих определенный фармакодинамически эффективный период, и антигена для индукции иммунной толерантности |